Table 1 Hypotensive events in several studies investigating carvedilol in cirrhosis
From: Severe carvedilol toxicity without overdose – caution in cirrhosis
Study (n = number of patients on carvedilol) | Daily dose of carvedilol (mg) studied | Follow up time(s) | Incidence of hypotension or bradycardia* |
|---|---|---|---|
Hobolth et al. (21) | 3.125–25 (mean 14 ± 7) | 90 min; 92.7 ± 13.6 days | 0 |
Stanley et al. (33) | 6.25–12.5 | 30.7 months (7.9–47.1) | 5 (15.2%) |
Tripathi et al. (77) | 12.5 | 26.2 ± 22.1 months | 2 (2.6%) |
De et al. (18) | 12.5–25 | 90 min; 7 days | 1 (5.6%) |
Banares et al. (14) | 25 | 60 min | 0 |
Bruha et al. (36) | 25 | 1 month | 0 |
Forrest et al. (16) | 25 | 60 min | 0 |
Lin et al. (11) | 25 | 90 min | 0 |
Stanley et al. (17) | 25 | 60 mins; 28 days | 3 (17.6%) |
Banares et al. (26) | 6.25–50 (mean 31 ± 4) | 11.1 ± 4.1 weeks | 2 (7.7%) |